
News|Articles|September 1, 2005
FDA actions in brief
Valsartan (Diovan, Novartis) received an expanded indication for reducing cardiovascular mortality in patients who are at high risk due to left ventricular failure or dysfunction after myocardial infarction.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Patient-facing EHR tool improves lung cancer screening identification
2
A jump in shingles after first Shingrix dose but the risk is transient, study finds
3
More evidence that the shingles vaccine may have protective effects beyond preventing shingles
4
DOD-funded study explores metformin as potential therapy for IPF
5




















































